Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris(University of Pittsburgh), Julie E. Bauman(George Washington University), Brian J Karlovits(Bon Secours Mercy Health), William E. Gooding(UPMC Hillman Cancer Center), David A. Clump(West Virginia University), Dwight E. Heron(Bon Secours Mercy Health), Ayana T. Ruffin(University of Pittsburgh), Carly Reeder(University of Pittsburgh), Tullia C. Bruno(University of Pittsburgh), Daniel P. Petro(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(City University of New York), Jessica Moskovitz(UPMC Hillman Cancer Center), Sheryl Kunning(University of Pittsburgh), James Ohr(University of Pittsburgh), Dario A.A. Vignali(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Jonas T. Johnson(University of Pittsburgh)
Cited by 32
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size
|Nature|1992|768
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688